Lisata Therapeutics Inc
LSTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$29.6M
Close$
$1.86
46.7% downside
Current Fair Value
46.7% downsideOvervalued by 46.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $29.60 Million |
|---|---|
| Enterprise Value | $16.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 0.81 |
| Outstanding Shares | 9,006,000 |
Return
| Return on Equity | -149.65% |
|---|---|
| Return on Assets | -116.30% |
| Return on Invested Capital | -89.36% |
Valuation & Multiples
| P/E Ratio | -1.79 |
|---|---|
| PEG | 35.98 |
| Price to Sales | - |
| Price to Book Ratio | 3.48 |
| Enterprise Value to Revenue | 97.27 |
| Enterprise Value to EBIT | -1.72 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$94,351
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.18%▲ 3.99% |
|---|---|
| Total Invested | $5.27M▲ 288.24% |
| Investors Holding | 34▲ 9.00% |
ESG Score
No data
About Lisata Therapeutics Inc
24 employees
CEO: David Mazzo Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mec...